Pomerleau C S, Pomerleau O F, Majchrzak M J
Psychopharmacology (Berl). 1987;91(3):391-3. doi: 10.1007/BF00518198.
Acute administration of mecamylamine, a centrally active nicotinic cholinergic agonist, has been shown to increase amount of smoking as indicated by smoking topography (e.g., puff rate, puff duration), expired carbon monoxide changes, and other inferential measures. In the present study, subjects showed significantly greater increases in plasma nicotine following smoking of two high-nicotine research cigarettes when pretreated with mecamylamine than when pretreated with placebo, even though no significant differences in puff volume or puff number were detected. Interestingly, none of our subjects reported nausea, although some achieved plasma nicotine levels at which nausea would typically be expected. We attribute the observed increases in nicotine intake to compensatory behavior designed to overcome mecamylamine's blocking effects.
已表明，急性给予美加明（一种中枢活性烟碱型胆碱能激动剂）会增加吸烟量，这可通过吸烟行为特征（如抽吸频率、抽吸持续时间）、呼出一氧化碳变化及其他推断性指标得以体现。在本研究中，与给予安慰剂预处理相比，给予美加明预处理的受试者在吸两支高尼古丁研究香烟后，血浆尼古丁水平显著升高，尽管未检测到抽吸量或抽吸次数存在显著差异。有趣的是，我们的受试者均未报告有恶心感，尽管有些人达到了通常会预期出现恶心的血浆尼古丁水平。我们将观察到的尼古丁摄入量增加归因于旨在克服美加明阻断作用的代偿行为。
